Cargando…

Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs

RATIONALE: Results from clinical trials in patients with severe eosinophilic asthma have demonstrated that mepolizumab is well tolerated and is associated with improved asthma control as evidenced by reductions in both exacerbations and maintenance oral corticosteroid use, and improvements in lung f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Llanos, Jean-Pierre, Ortega, Hector, Bogart, Michael, Packnett, Elizabeth R, Manjelievskaia, Janna, Bell, Christopher F, Hahn, Beth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996212/ https://www.ncbi.nlm.nih.gov/pubmed/32099413 http://dx.doi.org/10.2147/JAA.S236609

Ejemplares similares

Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study
por: Llanos, Jean-Pierre, et al.
Publicado: (2019)

Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma
por: Silver, Jared, et al.
Publicado: (2020)

Outcomes following mepolizumab treatment discontinuation: real-world experience from an open-label trial
por: Ortega, Hector, et al.
Publicado: (2019)

Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States
por: Silver, Jared, et al.
Publicado: (2023)

Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies
por: Casale, Thomas B., et al.
Publicado: (2022)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis
por: Harrison, Tim, et al.
Publicado: (2020)

Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
por: Walsh, Laura J., et al.
Publicado: (2023)

Effectiveness of mepolizumab in severe asthma in Japan: A real‐world study using claims data
por: Nagase, Hiroyuki, et al.
Publicado: (2021)

Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)
por: Korn, Stephanie, et al.
Publicado: (2023)

Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports
por: Pini, Laura, et al.
Publicado: (2021)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma
por: YILMAZ, İnsu, et al.
Publicado: (2021)

Health characteristics of patients with asthma, COPD and asthma–COPD overlap in the NHANES database
por: Llanos, Jean-Pierre, et al.
Publicado: (2018)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
por: Kayser, Moritz Z, et al.
Publicado: (2021)

Severe Pediatric Asthma Therapy: Mepolizumab
por: Ullmann, Nicola, et al.
Publicado: (2022)

Mepolizumab and COPD in Real Life
por: Revuelta-Salgado, Fernando, et al.
Publicado: (2021)

Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis
por: Charles, David, et al.
Publicado: (2022)

Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis
por: Kroes, Johannes A., et al.
Publicado: (2023)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

May mepolizumab used in asthma correct subfertility?
por: Ozden, Guzin, et al.
Publicado: (2021)

REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study
por: Domingo Ribas, Christian, et al.
Publicado: (2021)

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
por: Crimi, Claudia, et al.
Publicado: (2020)

Effects of Asthma Medication Type on Asthma Exacerbation in a Real-World Setting
por: Choi, Yong Jun, et al.
Publicado: (2022)

Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study
por: Domingo Ribas , Christian, et al.
Publicado: (2021)

Characteristics of new adult users of mepolizumab with asthma in the USA
por: Wu, Ann Chen, et al.
Publicado: (2021)

Daily Physical Activity in Asthma and the Effect of Mepolizumab Therapy
por: Panagiotou, Marios, et al.
Publicado: (2022)

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
por: Magnan, A., et al.
Publicado: (2016)

Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report
por: Caruso, C., et al.
Publicado: (2020)

A Comparison of the Effectiveness of Asthma Medications on Asthma Exacerbations in Real World National Cohort
por: Park, Hye Jung, et al.
Publicado: (2022)

Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma()()
por: Bölke, Georg, et al.
Publicado: (2022)

Real-Life Performance of Mepolizumab in T2-High Severe Refractory Asthma with the Overlapping Eosinophilic-Allergic Phenotype
por: González-Pérez, Ruperto, et al.
Publicado: (2022)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

Mepolizumab does not alter the blood basophil count in severe asthma
por: Wright, Adam Kelvin Alec, et al.
Publicado: (2019)

Role of mepolizumab in severe allergic asthma with vocal cord polyp
por: Karim, Azmat, et al.
Publicado: (2022)

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA
por: Albers, Frank C., et al.
Publicado: (2019)

Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use
por: Kimura, Yuya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r6pigep9d3g7381i509l61hf5k